Vis enkel innførsel

dc.contributor.authorLohse, Ansgar W.
dc.contributor.authorSebode, Marcial
dc.contributor.authorJørgensen, Marianne H.
dc.contributor.authorYtting, Henriette
dc.contributor.authorKarlsen, Tom Hemming
dc.contributor.authorKelly, Deirdre
dc.contributor.authorManns, Michael P.
dc.contributor.authorVesterhus, Mette
dc.date.accessioned2021-06-07T08:25:35Z
dc.date.available2021-06-07T08:25:35Z
dc.date.created2020-10-08T19:21:03Z
dc.date.issued2020
dc.PublishedJournal of Hepatology. 2020, 1-12.
dc.identifier.issn0168-8278
dc.identifier.urihttps://hdl.handle.net/11250/2758095
dc.description.abstractMost patients with autoimmune hepatitis respond well to standard immunosuppressive therapy with steroids and azathioprine, and while untreated disease is usually fatal, patients who respond well to therapy have an excellent prognosis. However, insufficient response to standard therapy or intolerable side effects requiring dose adaptions or treatment changes occur in 10–20% of patients. While there is fairly good agreement on second-line treatment options, there is very wide variation in the indication and use of possible third-line therapies. Herein, the European Reference Network on Hepatological Diseases (ERN RARE-LIVER) and the International Autoimmune Hepatitis Group (IAIHG) outline a treatment algorithm for both children and adults that should help to standardise treatment approaches, in order to improve patient care and to enable the comparison of treatment results between scientific publications.en_US
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.rightsNavngivelse-IkkeKommersiell-Ingen bearbeidelser 4.0 Internasjonal
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/deed.no
dc.titleSecond-line and Third-line therapy for Autoimmune Hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Groupen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionacceptedVersionen_US
dc.rights.holderCopyright 2020 Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.en_US
cristin.ispublishedtrue
cristin.fulltextpostprint
cristin.fulltextpostprint
cristin.qualitycode2
dc.identifier.doi10.1016/j.jhep.2020.07.023
dc.identifier.cristin1838311
dc.source.journalJournal of Hepatologyen_US
dc.source.pagenumber1496-1506en_US
dc.identifier.citationJournal of Hepatology. 2020, 73 (6), 1496-1506.en_US
dc.source.volume73en_US
dc.source.issue6en_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse-IkkeKommersiell-Ingen bearbeidelser 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse-IkkeKommersiell-Ingen bearbeidelser 4.0 Internasjonal